Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer Metastatic Clinical Trial

Official title:

A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01487863
• Other study ID #: P11-3
• Status: Completed
• Phase: Phase 2
• Start date: December 2011
• Est. completion date: June 2016

Study information

• Verified date: March 2019
• Source: Dendreon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters), and to assess the safety and efficacy of sipuleucel-T with concurrent or sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer.

Description:

Subjects underwent screening procedures at the Screening Visit to ensure that they met the inclusion and exclusion criteria outlined in the protocol. Subjects were evaluated for eligibility criteria, and if eligible, were registered and randomized in a 1:1 into either the Concurrent Arm or the Sequential Arm.

Subjects in both arms underwent a standard 1.5 to 2.0 blood volume leukapheresis, followed approximately 3 days later by an intravenous (IV) infusion of sipuleucel-T. This process occurred at approximately 2-week intervals. A course of sipuleucel-T treatment comprised three infusions.

Following the first infusion, subjects were limited to a maximum of three total product failures for all subsequent infusions, due specifically to insufficient total nucleated cell (TNC) count and/or CD54 upregulation. These subjects received no further leukaphereses or sipuleucel-T infusions, but did receive abiraterone acetate plus prednisone per the schedule of the arm to which they were randomized. All subjects received a total of 26 weeks of abiraterone acetate plus prednisone therapy.

All immune monitoring (IM) endpoints were collected from all subjects who received at least one infusion. Cellular and serological immune responses were assessed for subjects in both arms. In both arms, IM blood samples were collected at baseline (screening); pre-leukapheresis 2 and 3; post-infusion 1, 2, and 3; and weeks 6, 10, 14, and 26, with the timing of IM visits based on the onset of treatment (Day 0). Day 0 was the day of the first infusion. Post-infusion blood draws occurred at 3 hours (allowable window 1-24 hours) after each infusion. If a subject received only one or two infusions, immune samples were still drawn at the scheduled time points based on the first infusion (Day 0). If the subject was not scheduled to undergo further leukapheresis, no other pre-leukapheresis procedures were conducted.

During the active follow-up phase, subjects were followed from registration through the Post-Treatment Visit (30-37 days post-last study treatment), or until disease progression, unacceptable toxicity, or death, whichever occurred first.

During the long-term follow-up (LTFU) phase, subjects were followed from the Post-Treatment Visit for up to 3 years from the date of registration/randomization. During the LTFU phase, only new treatment-related serious adverse event (SAE)s, cerebrovascular event (CVE)s (regardless of causality), the first anti-cancer therapy and first chemotherapy, and survival status were collected via a quarterly telephone call.

Overall survival was measured as the time from randomization until death over a 3-year period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: June 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• histologically documented prostate cancer confirmed by a pathology report from prostate biopsy or radical prostatectomy specimen

• metastatic status as evidenced by imaging obtained </= 56 days prior to registration demonstrating bone metastasis or lymph node metastasis

• castrate resistant prostate cancer: castrate levels of testosterone (</= 50 ng/dL); evidence of disease progression concomitant with surgical or medical castration

• serum PSA >/= 2.0 ng/mL

• castrate levels of testosterone (</= 50 ng/dL) achieved via medical or surgical castration

• baseline Eastern Cooperative Oncology Group (ECOG) performance status of </= 1

• systolic blood pressure (BP) </= 140 mm Hg and diastolic BP </= 90 mm Hg at screening

• adequate baseline hematologic, renal, and liver functions

• must live in a permanent residence within a comfortable driving distance (round trip within one day) of the clinical trial site

Exclusion Criteria:

• the presence of known lung, liver, or brain metastases, malignant pleural effusions, or malignant ascites

• New York Heart Association Class III or IV heart failure

• any medical condition that may be compromised by increases in blood pressure, hypokalemia, or fluid retention

• Child-Pugh Class B or C hepatic insufficiency

• spinal cord compression, imminent long bone fracture, or any other condition likely to require radiation therapy and/or steroids for pain control

• known adrenalcortical insufficiency

• any medical contraindications to receiving prednisone

• prior treatment with sipuleucel-T

• previous treatment with abiraterone acetate (Zytiga(R)) or ipilimumab (Yervoy(TM))

• a requirement for systemic immunosuppressive therapy for any reason. Use of inhaled, intra-nasal, intra-articular, and topical steroids was allowed.

• treatment with any investigational vaccine or immunotherapy

• treatment with any chemotherapy prior to registration.

• a history of stage III or greater cancer, excluding prostate cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for = 3 years at the time of registration.

• myocardial infarction or ventricular or atrial arrhythmia within 6 months prior to registration

• ongoing anti-androgen withdrawal response.

• systemic steroid use within = 60 days of registration

• treatment with denosumab (Xgeva(R) or Prolia (R)) within = 3 months prior to registration

• positive test for human immunodeficiency virus (HIV) or human T cell lymphotrophic virus (HTLV) infections. Subjects with a positive test for hepatitis B or hepatitis C were allowed provided they meet the liver function test (LFT) criteria and have no signs of acute infection or active disease.

• treatment with any of the following medications or interventions within 28 days prior to registration: external beam radiation or major surgery requiring general anesthetic; saw palmetto; megestrol acetate (Megace(R)), diethylstilbestrol, and cyproterone; 5-alpha-reductase inhibitors (e.g. finasteride [Proscar(R)], dutasteride [Avodart(R)]); steroidal anti-androgen therapy; any other systemic therapy for prostate cancer, except for medical castration; treatment with any other investigational product for prostate cancer; substrates of CYP2D6 (e.g. including but not limited to thioridazine); inhibitors of CYP3A4 (e.g. including but not limited to ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin, and voriconazole); inducers of CYP3A4 (e.g. including but not limited to phenytoin, carbamazepine, rifampin, rifapentine, and phenobarbital)

• a requirement for treatment with opioid analgesics within 21 days prior to registration

• an active infection or infection requiring parenteral antibiotic therapy or causing fever within 7 days of registration

• any medical intervention, or other condition, or any other circumstance that, in the opinion of the Investigator or the Dendreon Medical Monitor, could compromise adherence with study requirements or otherwise compromise the study's objectives

Related Conditions & MeSH terms

• Castration-resistant Prostate Cancer
• Hormone Refractory Prostate Cancer
• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Biological:
• sipuleucel-T
Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Drug:
• abiraterone acetate
Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.

Locations

Country	Name	City	State
United States	The Urology Center of Colorado	Denver	Colorado
United States	Mid Atlantic Urology Associates, Mid Atlantic Clinical Research	Greenbelt	Maryland
United States	Indiana University	Indianapolis	Indiana
United States	Moores UCSD Cancer Center	La Jolla	California
United States	UCSD Medical Center - La Jolla	La Jolla	California
United States	Cancer Center Oncology Medical Group	La Mesa	California
United States	Carolina Urologic Research Center	Myrtle Beach	South Carolina
United States	Urology Associates, P.C.	Nashville	Tennessee
United States	NYU Clinical Cancer Center, NYU Langone Medical Center	New York	New York
United States	The Mount Sinai Medical Center	New York	New York
United States	GU Research Center, LLC	Omaha	Nebraska
United States	Associated Medical Professionals of NY, PLLC	Oneida	New York
United States	Providence Cancer Center Oncology and Hematology Care	Portland	Oregon
United States	Medical Oncology Associates - SD	San Diego	California
United States	Sharp Rees-Stealy	San Diego	California
United States	UCSD Medical Center - Hillcrest	San Diego	California
United States	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California
United States	Virginia Mason Medical Center	Seattle	Washington
United States	Associated Medical Professionals of New York, PLLC	Syracuse	New York
United States	Urology of Virginia	Virginia Beach	Virginia
United States	Georgetown University Medical Center - Lombardi Cancer Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Dendreon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative CD54 Upregulation Ratio Between the Cohorts.	An analysis of variance model for the log transformed cumulative CD54 upregulation ratio (CD54 upregulation is the fold increase in the final product (FP) from buoyant density separations (BDS) step 65. BDS65 step refers to sample taken after both BDS77 and BDS65 but before ex vivo culture in the presence of antigen PA2024. FP refers to sample taken after ex vivo culture) that includes the antigen concentration cohort as the independent variable was performed. Subjects who received all 3 infusions were included.	Over the course of sipuleucel-T therapy (approximately 1 month)